In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes

References

• Basheer L, Kerem Z. 2015. Interactions between CYP3A4 and dietary polyphenols. Oxid Med Cell Longev. 2015:854015.
   PubMed Web of Science ®Google Scholar
• Bedada SK, Neerati P. 2018. The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects. Eur J Clin Pharmacol. 74(1):91–97.
   PubMed Web of Science ®Google Scholar
• Bun SS, Laget M, Chea A, Bun H, Ollivier E, Elias R. 2009. Cytotoxic activity of alkaloids isolated from Stephania rotunda. Phytother Res. 23(4):587–590.
   PubMed Web of Science ®Google Scholar
• Chang YP, Huang CC, Shen CC, Tsai KC, Ueng YF. 2015. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet. 30(5):374–383.
   PubMed Web of Science ®Google Scholar
• Desgrouas C, Chapus C, Desplans J, Travaille C, Pascual A, Baghdikian B, Ollivier E, Parzy D, Taudon N. 2014. In vitro antiplasmodial activity of cepharanthine. Malar J. 13(1):327–337.
   PubMedGoogle Scholar
• Ericsson T, Sundell J, Torkelsson A, Hoffmann KJ, Ashton M. 2014. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica. 44:615–626.
   Google Scholar
• Fujii T, Sato T, Tamura A, Kometani M, Nakao K, Fujitani K, Kodama K, Akasu M. 1988. Structure-activity relationships of 4′-O-substituted 1-benzylisoquinolines with respect to their actions on the cell membrane of blood platelets and erythrocytes. Eur J Pharmacol. 146(2–3):285–290.
   PubMed Web of Science ®Google Scholar
• Furusawa S, Wu J. 2007. The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci. 80(12):1073–1079.
   PubMed Web of Science ®Google Scholar
• Hao X, Yuan J, Xu Y, Wang Z, Hou J, Hu T. 2018. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica. 48(12):1185–1191.
   PubMed Web of Science ®Google Scholar
• He YQ, Yang L, Liu Y, Zhang JW, Tang J, Su J, Li YY, Lu YI, Wang CH, Yang L, et al. 2009. Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry. Acta Pharmacol Sin. 30(10):1462–1470.
   PubMed Web of Science ®Google Scholar
• Hu X, Huang W, Yang Y. 2015. Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet. 40:373–377.
   Google Scholar
• Huang Y, Zhao J, Jian W, Wang G. 2018. Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. Xenobiotica. 48(8):839–844.
   PubMed Web of Science ®Google Scholar
• Jia Y, Liu J, Xu J. 2018. Influence of grapefruit juice on pharmacokinetics of triptolide in rats grapefruit juice on the effects of triptolide. Xen obiotica. 48(4):407–411.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jiang X, Li C, Xue H, Zhang X. 2016. Development of an IgY antibody-based immunoassay for the screening of the CYP2E1 inhibitor/enhancer from herbal medicines. Front Pharmacol. 7:502–512.
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol. 38:461–499.
   Google Scholar
• Kao M, Yang C, Chou W, Sheu J, Huang C. 2015. Cepharanthine mitigates lung injury in lower limb ischemia-reperfusion. J Surg Res. 199(2):647–656.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H, Shimada T, Nishiwaki K, Sakai O. 1992. High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura. [Rinshō Ketsueki] Jpn J Clin Hematol. 33:405.
   PubMedGoogle Scholar
• Kometani M, Kanaho Y, Sato T, Fujii T. 1985. Inhibitory effect of cepharanthine on collagen-induced activation in rabbit platelets. Eur J Pharmacol. 111(1):97–105.
   PubMed Web of Science ®Google Scholar
• Lang J, Li W, Zhao J, Wang K, Chen D. 2016. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica. 47:849–855.
   Web of Science ®Google Scholar
• Li A. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today. 6(7):357–366.
   PubMed Web of Science ®Google Scholar
• Liu T, Qian G, Wang W, Zhang Y. 2015. Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet. 40:235–238.
   Google Scholar
• Lim Y, Chen W, Cheng C, Ma W, Lin Y, Chen C, Hung D, Chen J, Yokoi T, Nakajima M, et al. 2014. Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med. 80:1097–1106.
   PubMed Web of Science ®Google Scholar
• Liu L, Sun S, Rui H, Li X. 2017. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol. 55(1):1868–1874.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• Nakazawa N, Nagatsuka S, Yukawa O. 1986. Effects of membrane stabilizing agents and radiation on liposomal membranes. Drugs Exp Clin Res. 12:831–835.
   PubMedGoogle Scholar
• Nomoto S, Imada H, Ohguri T, Yahara K, Kato F, Morioka T, Korogi Y. 2004. Effect of cepharanthin in preventing radiation induced normal tissue damage in prostate cancer. Gan Kagaku Ryoho. 31(7):1063–1066.
   PubMedGoogle Scholar
• Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PCK, Er HM, Ong CE. 2010. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J Ethnopharmacol. 130(2):275–283.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
   PubMed Web of Science ®Google Scholar
• Rogosnitzky M, Danks R. 2011. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacological Rep Pr. 63(2):337–347.
   PubMed Web of Science ®Google Scholar
• Shinobu F, Jianghong W. 2007. The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci. 80:1073–1079.
   Google Scholar
• Srinivas NR. 2016. Clinical drug–drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: physiological role of enzymes and transporters. Gen Physiol Biophys. 35(03):243–258.
   PubMedGoogle Scholar
• Suzuki R, Hara M, Shindoh J, Matsumoto S, Noda Y, Gonda H, Tanaka H, Taki F, Takagi K. 1992. Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients. Gan Kagaku Ryoho Cancer Chemother. 19:647.
   PubMedGoogle Scholar
• Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Xu J, Ma HY, Liang S, Sun M, Karin G, Koyama Y, Hu R, Quehenberger O, Davidson NO, Dennis EA, et al. 2017. The role of human cytochrome P450 2E1 in liver inflammation and fibrosis. Hepatol Commun. 1(10):1043–1057.
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell G. 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem. 1(5):403–425.
   PubMedGoogle Scholar
• Zhang H, Ya G, Rui H. 2017. Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. Eur J Drug Metab Pharmacokinet. 42(1):89–98.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, et al. 2007. Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci. 10(4):496–503.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wu Y, Wang D. 2018. Effects of glycyrrhizic acid on the pharmacokinetics of pristimerin in rats and its potential mechanism. Eur J Drug Metab Pharmacokinet. 43(1):63–68.
   PubMed Web of Science ®Google Scholar